Group 1 - The company is currently in the registration process for its self-expanding intracranial drug-coated stent system, which is expected to receive market approval by 2025 [2] - The company has stated that it is unable to predict the revenue and profit contributions from the product post-launch [2]

Core Industry Development - The biopharmaceutical sector is identified as the "number one industry" in Suzhou and a core industry in Wuzhong District, with a complete industrial chain from early drug development to clinical research [1] - Wuzhong District has developed a strong innovation cluster in biopharmaceuticals, becoming a comprehensive R&D hub in the Yangtze River Delta region [1] Regulatory Support and Services - Wuzhong District's market supervision bureau has implemented tailored services for biopharmaceutical companies, facilitating faster product approvals, exemplified by the approval of a unique pain relief gel by Leming Pharmaceutical [2][3] - The district has established a "white list" system to address import difficulties for R&D materials, enhancing the development capabilities of local biopharmaceutical firms [3] Knowledge and Intellectual Property Protection - The district has strengthened intellectual property protection, increasing funding for biopharmaceutical innovation, with a 30% increase in rewards for patent achievements [5] - A rapid patent review process has been introduced, reducing the time for patent approval from two years to as little as two to three months, benefiting 104 local biopharmaceutical companies [6] Quality Assurance and Standards - Wuzhong District has launched initiatives to enhance quality standards in the biopharmaceutical industry, including the establishment of a quality empowerment station to provide comprehensive services [7] - The district has published a white paper on the standardization of the biopharmaceutical and health industry, clarifying development paths and directions [7] Future Plans and Strategic Development - The market supervision bureau plans to create a database of certified biopharmaceutical companies and develop service lists for major projects and key enterprises to improve service precision and effectiveness [8]